

MANHATTAN PHARMACEUTICALS INC
Form SC 13G
December 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Manhattan Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$.001 per share

(Title of Class of Securities)

563118207

(CUSIP NUMBER)

December 15, 2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

// Rule 13d-1(b)
/X/ Rule 13d-1(c)
// Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form SC 13G

810 Seventh Avenue, 4th Floor
New York, New York 10019

- Item 2(a). Name of Person Filing:
Lester E. Lipschutz
- Item 2(b). Address of Principal Business Office or, if None, Residence:
Wolf, Block, Schorr and Solis-Cohen, LLP
1650 Arch Street- 22nd Floor
Philadelphia, PA 19103
- Item 2(c). Citizenship:
United States
- Item 2(d). Title of Class of Securities:
Common Stock
- Item 2(e). CUSIP Number:
563118207

- Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
Not Applicable
- (a) Broker or dealer registered under Section 15 of the Exchange Act;
 - (b) Bank as defined in Section 3(a)(6) of the Exchange Act;
 - (c) Insurance Company as defined in Section 3(a)(19) of the Exchange Act;
 - (d) Investment Company registered under Section 8 of the Investment Company Exchange Act;
 - (e) Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

SCHEDULE 13G

=====
CUSIP No. 563118207
=====

=====
Page 4 of 5 Pages
=====

- (f) Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) Parent Holding Company or Control Person in accordance with Rule 13d-1(b)(1)(ii)(G);

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form SC 13G

- (h) [] Saving Association as defined in Section 3(b) of The Federal Deposit Insurance Act;
- (i) [] Church Plan that is excluded from the definition of an Investment Company under Section 3(c)(14) of the Investment Company Act;
- (j) [] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

(a) Amount beneficially owned: Mr. Lipschutz may be deemed the beneficial owner of 3,982,368. Beneficial ownership consists of voting and dispositive power over (i) 3,133,912 shares owned by the Rosenwald 2000 Family Trusts for which Mr. Lipschutz is the trustee (none of which trusts own individually more than 5% of the issuer's securities), which consists of 2,913,057 shares and 24,294 shares of preferred stock that are convertible into 220,855 shares; (ii) 294,314 shares owned by the Lindsay A. Rosenwald 2000 (Delaware) Irrevocable Indenture of Trust, for which Mr. Lipschutz serves as the adviser; (iii) 277,071 shares owned by the Lindsay A. Rosenwald Alaska Irrevocable Indenture of Trust for which Mr. Lipschutz serves as the trustee; and (iv) 277,071 shares owned by the Lindsay A. Rosenwald Rhode Island Irrevocable Indenture of Trust for which Mr. Lipschutz serves as the adviser. Mr. Lipschutz disclaims beneficial ownership of these securities and the filing of this report is not an admission that Mr. Lipschutz is the beneficial owner of these securities.

(b) Percent of Class: 14.4%(1)

(c) Number of shares as to which such person has:

- (i) Sole power to vote or direct the vote: 3,982,368
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or direct the disposition of: 3,982,368
- (iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: Not Applicable.

SCHEDULE 13G

=====
CUSIP No. 563118207
=====

=====
Page 5 of 5 Pages
=====

Edgar Filing: MANHATTAN PHARMACEUTICALS INC - Form SC 13G

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

As of December 15, 2004, Mr. Lipschutz serves as (i) trustee of the Rosenwald 2000 Family Trusts; (ii) adviser of the Lindsay A. Rosenwald 2000 (Delaware) Irrevocable Indenture of Trust; (iii) trustee of the Lindsay A. Rosenwald Alaska Irrevocable Indenture of Trust; and (iv) adviser of the Lindsay A. Rosenwald Rhode Island Irrevocable Indenture of Trust. Mr. Lipschutz has the power to direct receipt of the proceeds from a sale of the shares owned by each such trust.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 16, 2004

(Date)

Lester E. Lipschutz

(Signature)

Lester E. Lipschutz

(Name/Title)

(1) Based on 27,540,495 shares reported issued and outstanding at November 12, 2004

